Spyre Therapeutics, Inc. — Director's Dealing 2025

Jan 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Spyre Therapeutics, Inc. (SYRE)
CIK: 0001636282
Period of Report: 2025-01-15

Reporting Person: Sloan Sheldon (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-01-15	Stock Option (Right to Buy)	$21.66	A	95500	Acquired	2035-01-15	Common Stock (95500)	Direct

Footnotes

F1: This option represents a right to purchase 95,500 shares of the Issuer's common stock, which will vest in equal monthly installments over four years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.